DK2280021T3
(en)
|
1999-06-29 |
2016-05-02 |
Mannkind Corp |
Pharmaceutical formulations comprising insulin complexed to a diketopiperazine
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
EP1294757B1
(fr)
*
|
2000-06-16 |
2006-11-22 |
Eli Lilly And Company |
Analogues de glp-1 (glucagone-like peptide 1)
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
EP1326630B1
(fr)
*
|
2000-09-18 |
2008-05-28 |
Sanos Bioscience A/S |
Utilisation de peptides glp-2
|
US20030119734A1
(en)
*
|
2001-06-28 |
2003-06-26 |
Flink James M. |
Stable formulation of modified GLP-1
|
CN1363654A
(zh)
|
2001-07-19 |
2002-08-14 |
上海华谊生物技术有限公司 |
生产促胰岛素分泌肽glp-1(7-36)的基因工程菌以及生产glp-1(7-36)的方法
|
HUP0501192A3
(en)
*
|
2001-08-23 |
2006-06-28 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
MXPA04003553A
(es)
*
|
2001-10-18 |
2004-07-22 |
Bristol Myers Squibb Co |
Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
|
EP2261250B1
(fr)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
Protéines de fusion d'albumine et GCSF
|
JP2005516968A
(ja)
*
|
2001-12-29 |
2005-06-09 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
|
ES2614603T3
(es)
*
|
2002-02-20 |
2017-06-01 |
Emisphere Technologies, Inc. |
Procedimiento de administración de moléculas GLP-1
|
ES2300568T3
(es)
|
2002-03-20 |
2008-06-16 |
Mannkind Corporation |
Aparato de inhalacion.
|
AU2003239478A1
(en)
*
|
2002-06-04 |
2003-12-22 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
US8372804B2
(en)
*
|
2007-10-24 |
2013-02-12 |
Mannkind Corporation |
Delivery of active agents
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
WO2004067548A2
(fr)
*
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Metabolites chimiquement modifies de peptides regulateurs et methodes de production et d'utilisation associees
|
ES2336563T3
(es)
|
2003-02-19 |
2010-04-14 |
Ipsen Pharma |
Analogos de glp-1.
|
JP4699374B2
(ja)
|
2003-05-15 |
2011-06-08 |
トラスティーズ オブ タフツ カレッジ |
安定なペプチド及びポリペプチドアナログ治療剤
|
ES2425221T3
(es)
*
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
ES2380437T3
(es)
*
|
2003-06-03 |
2012-05-11 |
Novo Nordisk A/S |
Composiciones farmacéuticas de péptido GLP-1 estabilizadas
|
EP1633391B1
(fr)
*
|
2003-06-03 |
2011-10-19 |
Novo Nordisk A/S |
Compositions peptidiques pharmaceutiques stabilisees
|
WO2005000892A2
(fr)
|
2003-06-12 |
2005-01-06 |
Eli Lilly And Company |
Proteines hybrides analogues de glp-1
|
SI3300721T1
(sl)
*
|
2003-11-20 |
2019-07-31 |
Novo Nordisk A/S |
Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
|
DE602004031455D1
(de)
|
2003-12-09 |
2011-03-31 |
Novo Nordisk As |
Regulierung der nahrungspräferenz mit glp-1-agonisten
|
WO2005058955A1
(fr)
*
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Analogues du glp-1
|
CA2550695A1
(fr)
*
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R |
Compositions pharmaceutiques glp-1
|
CA2552526A1
(fr)
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Analogues peptidiques 1 semblables au glucagon a action de longue duree
|
PT2308976E
(pt)
|
2004-04-30 |
2013-05-17 |
Dow Agrosciences Llc |
Novo gene de resistência a herbicida
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
WO2005120492A1
(fr)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
|
DE602005024413D1
(de)
|
2004-08-20 |
2010-12-09 |
Mannkind Corp |
Katalyse der diketopiperazinsynthese
|
AU2005277041B2
(en)
|
2004-08-23 |
2012-03-22 |
Mannkind Corporation |
Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
|
ES2442223T3
(es)
*
|
2004-08-31 |
2014-02-10 |
Novo Nordisk A/S |
Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
|
EP1799710A2
(fr)
*
|
2004-10-07 |
2007-06-27 |
Novo Nordisk A/S |
Composes de glp-1 a action prolongee
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
ES2735533T3
(es)
|
2004-11-12 |
2019-12-19 |
Novo Nordisk As |
Formulaciones estables de GLP-1
|
EP2505207B1
(fr)
|
2005-01-14 |
2015-04-22 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Exendines modifiées et utilisations correspondantes
|
WO2006083761A2
(fr)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solutions de solvant/polymere utilisees comme vehicules de suspension
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
JPWO2006098524A1
(ja)
*
|
2005-03-18 |
2008-08-28 |
味の素株式会社 |
ストレスによる腸疾患の予防・治療剤
|
ME02786B
(fr)
*
|
2005-05-13 |
2011-10-31 |
Lilly Co Eli |
Composes glp-1 pegyles
|
CN101258163B
(zh)
*
|
2005-06-30 |
2013-08-21 |
益普生制药股份有限公司 |
Glp-1药物组合物
|
US7799344B2
(en)
|
2005-09-14 |
2010-09-21 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
|
NZ608188A
(en)
|
2005-10-28 |
2014-10-31 |
Dow Agrosciences Llc |
Novel herbicide resistance genes
|
ES2572952T3
(es)
|
2005-11-07 |
2016-06-03 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
JP2009525946A
(ja)
|
2005-12-20 |
2009-07-16 |
デューク・ユニヴァーシティ |
増強された薬理学的性質を有する活性物質を送達するための方法および組成物
|
WO2008063203A2
(fr)
*
|
2006-01-27 |
2008-05-29 |
Whitehead Institute For Biomedical Research |
Compositions et méthodes de silençage efficace de gènes dans des végétaux
|
CN104383546B
(zh)
|
2006-02-22 |
2021-03-02 |
曼金德公司 |
用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
|
EP2574624A1
(fr)
*
|
2006-04-20 |
2013-04-03 |
Amgen Inc. |
Composés GLP-1
|
EP2020990B1
(fr)
|
2006-05-30 |
2010-09-22 |
Intarcia Therapeutics, Inc |
Modulateur de flux en deux pieces avec conduit interne pour un assemblage d'administration osmotique.
|
CN101466399B
(zh)
*
|
2006-06-09 |
2015-05-13 |
诺华股份有限公司 |
稳定的胰岛素样生长因子多肽
|
EP2044113A2
(fr)
*
|
2006-07-06 |
2009-04-08 |
Amylin Pharmaceuticals, Inc. |
Peptides semblables au glucagon et leurs utilisations
|
BRPI0714334A2
(pt)
*
|
2006-07-18 |
2013-05-14 |
Centocor Inc |
mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos
|
EP2363112B8
(fr)
|
2006-08-09 |
2018-11-21 |
Intarcia Therapeutics, Inc. |
Système de libération osmotique avec ENSEMBLE DE PISTON
|
KR100851560B1
(ko)
*
|
2006-12-27 |
2008-08-11 |
고려대학교 산학협력단 |
새로운 글루카곤 유사 펩타이드-1 (glp-1) 작용제 및 그용도
|
MX2009006564A
(es)
|
2007-01-05 |
2009-06-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.
|
CN101041693B
(zh)
*
|
2007-02-06 |
2011-08-17 |
珠海联邦制药股份有限公司 |
一种降血糖多肽及其应用
|
MX2009008241A
(es)
|
2007-02-15 |
2009-10-08 |
Univ Indiana Res & Tech Corp |
Co-agonistas de receptor de glucagon/glp-1.
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
GB2448895A
(en)
*
|
2007-05-01 |
2008-11-05 |
Activotec Spp Ltd |
GLP-1 like compounds and uses thereof
|
US8464239B2
(en)
*
|
2007-06-11 |
2013-06-11 |
Red Hat, Inc. |
Real-time installation and/or configuration assistant
|
ES2646614T3
(es)
|
2007-08-03 |
2017-12-14 |
Eli Lilly And Company |
Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
|
KR101736502B1
(ko)
*
|
2007-10-24 |
2017-05-16 |
맨카인드 코포레이션 |
Glp-1에 의한 유해 효과의 예방 방법
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
JP5669582B2
(ja)
|
2007-10-30 |
2015-02-12 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト
|
WO2009058734A1
(fr)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Composés présentant une activité d'antagoniste de glucagon et d'agoniste du glp-1
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
US8499757B2
(en)
|
2008-06-13 |
2013-08-06 |
Mannkind Corporation |
Dry powder inhaler and system for drug delivery
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
EA019203B9
(ru)
|
2008-06-17 |
2014-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты глюкагонового рецептора/glp-1-рецептора
|
JP5753779B2
(ja)
|
2008-06-17 |
2015-07-22 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
|
TWI474835B
(zh)
|
2008-06-17 |
2015-03-01 |
Univ Indiana Res & Tech Corp |
用於治療代謝病症及肥胖症之基於gip之混合激動劑
|
JP5479465B2
(ja)
|
2008-06-20 |
2014-04-23 |
マンカインド コーポレイション |
吸入努力をリアルタイムにプロファイルする対話式機器および方法
|
CA2726894A1
(fr)
*
|
2008-06-27 |
2009-12-30 |
Duke University |
Agents therapeutiques comprenant des peptides de type elastine
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
CN101337989B
(zh)
*
|
2008-08-28 |
2012-10-24 |
中国药科大学 |
一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN101367873B
(zh)
*
|
2008-10-08 |
2011-05-04 |
南开大学 |
一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
|
EP2344519B1
(fr)
|
2008-11-07 |
2016-09-28 |
The General Hospital Corporation |
Fragments c-terminaux du peptide 1 de type glucagon (glp-1)
|
PE20120332A1
(es)
|
2008-12-19 |
2012-04-14 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
EP2676695A3
(fr)
|
2009-03-11 |
2017-03-01 |
MannKind Corporation |
Appareil, système et procédé de mesure de résistance d'un inhalateur
|
KR20190090092A
(ko)
|
2009-06-12 |
2019-07-31 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
WO2010148089A1
(fr)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Composés de glucagon actifs sur le récepteur gip
|
EP2454282B1
(fr)
|
2009-07-13 |
2015-03-04 |
Zealand Pharma A/S |
Analogues de glucagon acetylees
|
HUE032703T2
(en)
*
|
2009-08-14 |
2017-10-30 |
Phasebio Pharmaceuticals Inc |
Modified vasoactive intestinal peptides
|
MX352878B
(es)
|
2009-09-28 |
2017-12-13 |
Intarcia Therapeutics Inc |
Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
|
EP2495255A4
(fr)
*
|
2009-10-30 |
2013-05-15 |
Otsuka Chemical Co Ltd |
Forme glycosylée d'analogue du glp-1 antigénique
|
JP5784622B2
(ja)
|
2009-11-03 |
2015-09-24 |
マンカインド コーポレ−ション |
吸入活動をシミュレートするための装置及び方法
|
CN102770152B
(zh)
|
2009-11-25 |
2016-07-06 |
阿瑞斯根股份有限公司 |
肽类的粘膜递送
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
CN102834108A
(zh)
|
2010-01-27 |
2012-12-19 |
印第安纳大学研究及科技有限公司 |
用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物
|
WO2011123943A1
(fr)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
|
MX2012013005A
(es)
|
2010-05-13 |
2013-02-26 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
|
WO2011143209A1
(fr)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
|
WO2011143788A1
(fr)
*
|
2010-05-17 |
2011-11-24 |
Zhejiang Beta Pharma Inc. |
Nouveaux analogues peptidiques de type glucagon, composition, et procédé d'utilisation
|
CN102985125A
(zh)
|
2010-06-21 |
2013-03-20 |
曼金德公司 |
干粉药物输送系统和方法
|
MX2012014576A
(es)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida.
|
EP2588490B1
(fr)
|
2010-07-02 |
2017-02-22 |
Angiochem Inc. |
Polypeptides courts contenant des acides aminés d pour conjugués thérapeutiques et leurs utilisations
|
WO2012061466A2
(fr)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Méthodes de traitement d'une maladie de stéatose
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
BR122020008875B8
(pt)
|
2011-04-01 |
2022-12-06 |
Mannkind Corp |
Embalagem de bolha e método de fabricação de uma embalagem de bolhas
|
CN102180963B
(zh)
*
|
2011-04-22 |
2014-06-25 |
中国药科大学 |
胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN102219850A
(zh)
*
|
2011-05-03 |
2011-10-19 |
上海格尼生物技术有限公司 |
新的长效glp-1化合物
|
ES2669190T3
(es)
|
2011-06-06 |
2018-05-24 |
Phasebio Pharmaceuticals, Inc. |
Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
|
WO2012174472A1
(fr)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
Microparticules de dicétopipérazine de capacité élevée
|
EA031230B1
(ru)
|
2011-06-22 |
2018-12-28 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Агонисты глюкагонового рецептора/glp-1-рецептора
|
CA2839867A1
(fr)
|
2011-06-22 |
2012-12-27 |
Indiana University Research And Technology Corporation |
Co-agonistes du recepteur du glucagon et du recepteur du gpl-1
|
EP2729157B1
(fr)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Un pentapeptide dérivé de l'extrémité c-terminale du glp-1 (glucagon-like peptide 1) pour le traitement
|
JP6352806B2
(ja)
*
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
BR112014009686A2
(pt)
|
2011-10-24 |
2018-08-07 |
Mannkind Corp |
composição analgésica inalável, pó seco e método para tratar dor
|
MX2014003579A
(es)
|
2011-11-17 |
2015-04-10 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
|
ES2602486T3
(es)
|
2012-06-21 |
2017-02-21 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran actividad de receptor de GIP
|
ES2624294T3
(es)
|
2012-07-12 |
2017-07-13 |
Mannkind Corporation |
Sistemas de suministro de fármacos en polvo seco
|
US10159644B2
(en)
|
2012-10-26 |
2018-12-25 |
Mannkind Corporation |
Inhalable vaccine compositions and methods
|
CN103087179A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087177A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087178A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087175A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087176A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CA2906817C
(fr)
|
2013-03-15 |
2022-01-18 |
Mannkind Corporation |
Compositions de dicetopiperazine microcristallines et procedes
|
PL2986313T3
(pl)
|
2013-04-18 |
2019-12-31 |
Novo Nordisk A/S |
Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
|
US9925144B2
(en)
|
2013-07-18 |
2018-03-27 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
CN105517607A
(zh)
|
2013-08-05 |
2016-04-20 |
曼金德公司 |
吹入设备和方法
|
CN104262481B
(zh)
*
|
2013-08-09 |
2018-02-09 |
天津药物研究院有限公司 |
一种侧链修饰的长效glp‑1类似物的制备方法及其应用
|
CN103405753B
(zh)
*
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
EP3139949B1
(fr)
|
2014-05-08 |
2020-07-29 |
Phasebio Pharmaceuticals, Inc. |
Compositions comprenant un protéine de fusion de vip-elp pour l'utilisation dans le traitement de la fibrose kystique
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
MA55068A
(fr)
*
|
2014-10-24 |
2022-01-05 |
Merck Sharp & Dohme |
Co-agonistes des récepteurs du glucagon et du glp-1
|
ES2822598T3
(es)
|
2015-02-09 |
2021-05-04 |
Phasebio Pharmaceuticals Inc |
Métodos y composiciones para tratar enfermedades y trastornos musculares
|
MX2017015504A
(es)
|
2015-06-03 |
2018-05-15 |
Intarcia Therapeutics Inc |
Sistemas de colocacion y remoción de implante.
|
BR112018013530A2
(pt)
*
|
2015-12-31 |
2018-12-04 |
Hanmi Pharm. Co., Ltd. |
?peptídeo isolado, polinucleotídeo e composição farmacêutica?
|
WO2017200943A1
(fr)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Polypeptides sélectifs du récepteur du glucagon et méthodes pour les employer
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
IL307966A
(en)
|
2017-01-03 |
2023-12-01 |
Intarcia Therapeutics Inc |
Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
WO2019038412A1
(fr)
|
2017-08-24 |
2019-02-28 |
Novo Nordisk A/S |
Compositions de glp-1 et leurs utilisations
|
WO2019140021A1
(fr)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Polythérapie
|
PE20211417A1
(es)
|
2018-04-05 |
2021-08-02 |
Sun Pharmaceutical Ind Ltd |
Analogos novedosos de glp-1
|
TWI705820B
(zh)
|
2018-06-22 |
2020-10-01 |
美商美國禮來大藥廠 |
Gip/glp1促效劑組合物
|
EP3864031A1
(fr)
|
2018-10-11 |
2021-08-18 |
Intarcia Therapeutics, Inc. |
Polypeptides analogues d'amyline humaine et procédés d'utilisation
|
KR20240044545A
(ko)
*
|
2018-10-30 |
2024-04-04 |
지아닝 리우 |
Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도
|
CA3056663C
(fr)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Utilisation du dulaglutide pour reduire le risque d'evenement cardiovasculaire chez les patients atteints du diabete de type 2
|
CN110845601B
(zh)
*
|
2019-10-12 |
2021-01-19 |
广东药科大学 |
不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
BR112022013746A2
(pt)
|
2020-02-18 |
2022-10-11 |
Novo Nordisk As |
Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa
|
US11981718B2
(en)
*
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|